Consejo Superior De Investigaciones Cientificas

The Governing Council of the University of Toronto

Temple University

University of North Carolina at Greensboro

Paula Morales Lazaro

Nadine Jagerovic

Dow P Hurst

Patricia H Reggio

Mary E Abood

Ruth Ross

Eugen Brailoiu

Luciana Magalhaes Leo

Ana Lago Fernández

Lauren Whyte

Nouroddin Sotoudeh Chafi

Pingwei Zhao

The present invention relates to pyrazolylbenzene-1,3-diols as cannabidiol derivatives, its use for the manufacture of a medicament, and more particularly, to the use of this medicament for the treatment and/or prevention of a disorder associated with the GPR18 and/or TRPV1 receptors and the use of these compounds for pharmacological assays related to GPR18 and/or TRPV1.

Pyrazolylbenzene-1,3-diols for diseases associated with g protein-coupled receptor 18 and in combination with transient receptor potential vanilloid 1

The present invention relates to a family of chromenopyrazole derivatives of formula (I): which have the ability to modulate the receptor of the cannabinoid family GPR55, whereby the invention also relates to the use of these compounds for the manufacture of a medicament for the treatment of diseases in which the GPR55 receptor has a physiological role such as diabetes, Parkinson's disease, multiple sclerosis, neuropathic pain, osteoporosis and cancers such as cholangiocarcinoma, breast cancer, ovarian and prostate cancer, glioblastoma, and cutaneous carcinoma.

Selective modulators of the activity of the GPR55 receptor: chromenopyrazole derivatives

Growing community of inventors

Madrid, Spain

Paula Morales Lazaro